alexa Glucagon-Like Peptide 1, Neuroprotection and Neurodegenerative Disorders | Open Access Journals
ISSN: 2167-7956
Journal of Biomolecular Research & Therapeutics
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Glucagon-Like Peptide 1, Neuroprotection and Neurodegenerative Disorders

Fedele E1,2*, Ricciarelli R3 and Rebosio C1

1Department of Pharmacy, Section of Pharmacology and Toxicology, University of Genoa, Italy

2Center of Excellence for Biomedical Research, University of Genoa, Italy

3Department of Experimental Medicine, Section of General Pathology, University of Genoa, Italy

*Corresponding Author:
Fedele E
Department of Pharmacy
Section of Pharmacology and Toxicology
University of Genoa, Genova, Italy.
Tel: +39-010-3532659
E-mail: [email protected]

Received date: July 19, 2016; Accepted date: July 20, 2015; Published date: July 26, 2016

Citation: Fedele E, Ricciarelli R, Rebosio C (2016) Glucagon-Like Peptide 1, Neuroprotection and Neurodegenerative Disorders. J Biomol Res Ther 5:e151. doi:10.4172/2167-7956.1000e151

Copyright: © 2016 Fedele E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Biomolecular Research & Therapeutics

Editorial

Glucagon-Like Peptide 1 (GLP-1) is a hormone belonging to the family of incretins whose peripheral insulinotropic effects in maintaining glucose homeostasis in response to food ingestion have long been known [1]. GLP-1 (7-36), the most common and biologically active form, is a 30 amino acid peptide formed by post-translational cleavage of the pro-glucagon gene, it shows 50% homology to glucagon and it is mainly produced by enteroendocrine L-cells, which secrete it into the bloodstream. Although GLP-1 is blood brain barrier permeable, it is also synthesized in the brain and, in particular, in neurons of the nucleus tractus solitarius and of the intermediate reticular nucleus, which innervate the cerebral cortex, the hypothalamus, the amygdala, the hippocampal region and the paraventricular nucleus of the thalamus [2-5].

In the periphery, GLP-1 has a rather short half-life, being rapidly inactivated to GLP-1(9-36) amide by dipetidyl peptidase IV (DPP-IV) [6,7] an enzyme which is present in peripheral tissues, in body fluids (i.e., blood plasma and cerebrospinal fluid) and seems to localize also in the brain [8-10].

GLP-1 acts by activating a classic 7TM-G-protein coupled receptor named GLP-1R that, in the functional studies carried out so far, has been shown to stimulate adenylyl cyclase via the α subunit of the Gs protein, thus increasing intracellular cAMP levels and triggering a cascade of downstream events, such as activation of PKA, Epac2, PKC, MAPK and PI-3K pathways. However, it has been reported that GLP-1R can also couple to other G-protein α-subunits (i.e., Gq, o, i), although the functional meaning of this molecular promiscuity is not fully understood [11].

A milestone in the understanding of the physiological roles of the GLP-1/GLP-1R system was the isolation and characterization of the DPP-IV resistant, BBB permeable GLP-1R selective agonist exendin-4 and the selective antagonist exendin-(9-39) that permitted, in addition to in vitro experiments, to initiate various in vivo studies [12,13]. After exendin-4, liraglutide and lixisenatide have been produced as other GLP-1R agonists, whereas sitagliptin, saxagliptin and vidagliptin have been developed as selective DPP-IV inhibitors able to increase endogenous GLP-1 levels.

Although the interest for the GLP-1/GLP-1R system began in the field of diabetes treatment, it was soon clear that this hormone could also have important functions in the central nervous system.

The first evidence for a central physiological role of GLP-1, dates back to 1996 when it was shown that its intracerebroventricular (icv) administration, potently inhibited feeding in rats [14]. However, it was only six years later that the neuroprotective role GLP-1 and exendin-4 was demonstrated for the first time [15]. In that study, activation of GLP-1Rs was able to completely protect cultured rat hippocampal neurons from apoptotic death caused by glutamate excitotoxicity and to greatly reduce the in vivo ibotenic acid-induced depletion of choline acetyltransferase in the basal forebrain, leading the authors to hypothesise that “….such peptides may have potential for halting or reversing neurodegenerative processes in CNS disorders, such as Alzheimer’s disease…

Since then, a large body of evidence has accumulated indicating that the activation of GLP-1Rs could represent a novel and effective disease modifying therapeutic strategy for treating neurodegenerative disorders.

Indeed, both in vitro and in vivo studies using validated animal models of Alzheimer’s (AD) and Parkinson’s (PD) diseases, Huntington’s chorea, amyotrophic lateral sclerosis and stroke have undoubtedly demonstrated the protective properties of GLP-1R agonists using both anatomo-pathological and behavioural analysis [16-18].

Significant neuroprotection has been reported also for the DPP-4 inhibitors sitagliptin and saxagliptin in PD and AD animal models, as well as in models of cerebral ischemia [19-21]. However, administration of sitagliptin to type 2 diabetic rats has been found to aggravate γ-tau phosphorylation in the hippocampus, thus highlighting the need of further studies before considering its use in AD [22].

As for the possible mechanisms through which GLP-1Rs trigger neuroprotection, several studies have revealed that these receptors are capable of stimulating neurite outgrowth, promoting adult neurogenesis with cell proliferation and survival, interrupting proapoptotic processes, and reducing neuroinflammation. In addition, they have beneficial effects for mitochondrial functions by means of different molecular mechanisms, including the stabilisation of the outer membrane through activation of the PI3K/AKT pathway, thus preventing the initiation of the apoptotic intrinsic pathway [17,18]. Indeed, mitochondria dysfunctions represent a common feature of different neurodegenerative disorders.

It is also worth noting that GLP-1 and GLP-1R have important effects also on learning and memory formation both under physiological and pathological conditions. In fact, in rodents, icv administration of GLP-1 or GLP-1R overexpression resulted in the enhancement of learning and memory, whereas GLP-1R knock-out caused significant deficits in cognitive processes [23,24]. The pro-amnesic effects of GLP-1R agonists are associated with the facilitation of hippocampal long term potentiation (LTP), the electrophysiological substrate of memory, as measured both in vitro and in vivo [25,26]. Accordingly, this synaptic plasticity phenomenon is impaired in GLP-1R knockout mice [24]. Moreover, administration of GLP-1, GLP-1 agonists or DPP-IV inhibitors rescues LTP and the memory impairment caused by exogenous or endogenous β-amyloid, the self-aggregating peptide that accumulates AD brains [21,25-30].

Such overwhelming evidence has led to clinical trials in which GLP-1 mimetic have been tested for their efficacy in neurodegenerative disorders such as PD and AD.

In the first case, a single-blind proof of concept evaluated the progression of motor and nonmotor symptoms in a small group of PD patients treated with exenatide (exendin-4) administered subcutaneously for 12 months and found clinically relevant ameliorations both in motor and cognitive performances, evaluated by MDS-UPDRS (Movement Disorder Society Unified Parkinson’s Disease Rating Scale) and Mattis DRS-2 (Dementia Rating Scale 2) at the end of the therapy and after two months of washout [31]. Most interestingly, the improvement persisted 12 months after the trial, with exanetide-treated patients showing a 5.6 and 5.3 point advantage on the MDS-UPDRS part 3 and on the Mattis DRS-2, respectively [32]. These encouraging results have fuelled a larger, randomized, doubleblind, placebo-controlled phase II trial that is investigating the efficacy of a once weekly treatment with exenatide for 48 weeks in patients with moderate PD (NCT01971242).

As for AD, the efficacy of a six-month treatment with liraglutide has been evaluated in a small, randomized, double-blind, placebocontrolled trial on a total of 38 patients (18 liraglutide treated vs 20 placebo) [33]. The primary outcome was the change of brain β-amyloid deposit assessed by PIB (Pittsburgh compound B) PET scan, whereas secondary outcomes were changes in CMRglc (Cerebral Metabolic Rate of glucose consumption) measured by FDG (Fluoro Deoxy Glucose) PET scan and changes in cognition assessed by the WMS-IV (Wechsler Memory Scale IV). The results show that CMRglc significantly declined in placebo controls but not in liraglutide-treated patients. Actually, the values were increased in this group, although insignificantly. However, β-amyloid load and cognitive scores were not different between the two groups. At the moment, there are two ongoing randomized, double blind, phase II trials: a pilot study that will evaluate safety, tolerability and efficacy of exenatide on MCI (Mild Cognitive Impairment) and early AD (NCT01255163) with an estimated enrolment of 100 patients, and a safety/efficacy study of liraglutide on mild AD with an estimated enrolment of 206 patie nts (NCT01843075).

In conclusion, pre-clinical and clinical studies point to stimulation of GLP-1 receptors as a novel and promising neuroprotective pharmacological intervention to treat different neurodegenerative disorders with the hope of slowing their progression. Will these promises become reality

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 8102
  • [From(publication date):
    September-2016 - Nov 25, 2017]
  • Breakdown by view type
  • HTML page views : 8032
  • PDF downloads : 70
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords